A Phase III Study of GS101 Injection to Dupixent®

This is a a multicenter, randomized, double-blinded, parallel, positive-controlled, Phase III comparative study to evaluate GS101 Injection versus Dupixent® in participants with moderate-to-severe atopic dermatitis. A total of 572 subjects are planned to be included and randomized at a ratio of 1:1 to receive GS101 injection or Dupixent®

NCT Number	NCT07386743
Lead Sponsor	Jiangsu Genscend Biopharmaceutical Co., Ltd
Conditions	Atopic Dermatitis (AD)
Enrollment	572 participants
Start Date	2026-02
Primary Completion	2027-04 (estimated)
Study Completion	2028-01 (estimated)
Updated on ClinicalTrials.gov	2026-02-04